GLP-1/GIP/Glucagon triple receptor agonist
Retatrutide is an investigational triple-agonist peptide (GLP-1, GIP, and glucagon receptor agonist) developed by Eli Lilly that showed significant weight loss in Phase 2 clinical trials. It is not FDA-approved for any indication. The peptide has received high online attention from biohacking and fitness communities, requiring careful separation of clinical trial data from social media claims.
Track public claims and clinical trial progress. Do not publish dosing, sourcing, or treatment instructions. Separate clinical trial data from social media hype.
Phase 2 trial results published in NEJM showed dose-dependent weight loss up to 17.5% at 48 weeks, supporting advancement to Phase 3.
Retatrutide is not FDA-approved for any indication; Eli Lilly is the developer and the TRIUMPH Phase 3 program is ongoing.
High social media attention from fitness and biohacking creators, with multiple long-form YouTube videos accumulating hundreds of thousands of views.
Regulatory watch status maintained until Phase 3 data and FDA approval decisions are available.
Evidence level: Community discussion
Sources: YouTube — This Is Not Covered - Dr. Ashley Froese, YouTube — Quinn Stillson MD, YouTube — Dr Trevor Bachmeyer
Track as media claims that need checking against clinical trial data. Do not convert social media excitement into treatment guidance.
Evidence level: Peer reviewed
Sources: New England Journal of Medicine
Cite the NEJM Phase 2 publication directly. Phase 3 results are pending and this claim should be updated when those data are published.
Evidence level: Primary regulatory
Sources: ClinicalTrials.gov / U.S. National Library of Medicine
Confirm approval status against ClinicalTrials.gov and FDA records on each review cycle. Update immediately if regulatory status changes.
Evidence level: Community discussion
Sources: YouTube — Quinn Stillson MD, YouTube — Dr Trevor Bachmeyer, U.S. Food and Drug Administration
Track these discussions without endorsing them. The FDA warning letter context shows regulatory awareness of research-use-only positioning for peptide products.
Source records are stored in the repo and linked from each claim.
Phase 2 randomized trial of retatrutide (LY3437943), a triple GLP-1/GIP/glucagon receptor agonist, showing dose-dependent weight loss up to 17.5% at 48 weeks in adults with obesity.
ClinicalTrials.gov registry entry for the TRIUMPH Phase 3 trial program evaluating retatrutide for obesity, sponsored by Eli Lilly. Retatrutide is not FDA-approved for any indication.
Long-form YouTube video by a medical doctor discussing retatrutide with chapters on monitoring, diet, and exercise. Tracked as a media signal for public claim patterns.
High-view (600K+ views) YouTube explainer using strong outcome language about retatrutide for fat loss. Tracked as a media signal for high-attention claims.
Long-form YouTube masterclass format discussing retatrutide. Tracked as a discovery source for recurring public questions and claim patterns.
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.